Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK—a randomized controlled trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is a highly lethal condition. Early recognition of tissue hypoperfusion and its reversion are key factors for limiting progression to multiple organ dysfunction and death. Lactate-targeted resuscitation is the gold-standard under current guidelines, although it has several pitfalls including that non-hypoxic sources of lactate might predominate in an unknown proportion of patients. Peripheral perfusion-targeted resuscitation might provide a real-time response to increases in flow that could lead to a more timely decision to stop resuscitation, thus avoiding fluid overload and the risks of over-resuscitation. This article reports the rationale, study design and analysis plan of the ANDROMEDA-SHOCK Study. METHODS: ANDROMEDA-SHOCK is a randomized controlled trial which aims to determine if a peripheral perfusion-targeted resuscitation is associated with lower 28-day mortality compared to a lactate-targeted resuscitation in patients with septic shock with less than 4 h of diagnosis. Both groups will be treated with the same sequential approach during the 8-hour study period pursuing normalization of capillary refill time versus normalization or a decrease of more than 20% of lactate every 2 h. The common protocol starts with fluid responsiveness assessment and fluid loading in responders, followed by a vasopressor and an inodilator test if necessary. The primary outcome is 28-day mortality, and the secondary outcomes are: free days of mechanical ventilation, renal replacement therapy and vasopressor support during the first 28 days after randomization; multiple organ dysfunction during the first 72 h after randomization; intensive care unit and hospital lengths of stay; and all-cause mortality at 90-day. A sample size of 422 patients was calculated to detect a 15% absolute reduction in mortality in the peripheral perfusion group with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. CONCLUSIONS: If peripheral perfusion-targeted resuscitation improves 28-day mortality, this could lead to simplified algorithms, assessing almost in real-time the reperfusion process, and pursuing more physiologically sound objectives. At the end, it might prevent the risk of over-resuscitation and lead to a better utilization of intensive care unit resources. Trial registration ClinicalTrials.gov Identifier: NCT03078712 (registered retrospectively March 13th, 2017).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621 · cited 4×
“0 mmol/L as set by SSC [10] (b) Patients without a confirmed source of infection (as this could increase the translation of the study to other critically ill).”
BackgroundInfluentialSelf-citationDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Jansen, T. C., van Bommel, J., Schoonderbeek, F. J., Sleeswijk Visser, S. J., van der Klooster, J. M., Lima, A. P., Willemsen, S. P., & Bakker, J. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200912-1918oc · Cited by 894
Self-citationEarly, Goal-Directed Therapy for Septic Shock — A Patient-Level Meta-Analysis
The PRISM Investigators (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701380 · Cited by 600
The CLASSIC Trial Group, Hjortrup, P. B., The Scandinavian Critical Care Trials Group, Haase, N., Bundgaard, H., Thomsen, S. L., Winding, R., Pettilä, V., Aaen, A., Lodahl, D., et al. (2016) · Intensive Care Medicine · doi:10.1007/s00134-016-4500-7 · Cited by 376
Lara, B., Enberg, L., Ortega, M., Leon, P., Kripper, C., Aguilera, P., Kattan, E., Castro, R., Bakker, J., & Hernandez, G. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188548 · Cited by 167
Self-citation
Cited by
Hernández, G., Ospina-Tascón, G. A., Damiani, L. P., Estenssoro, E., Dubin, A., Hurtado, J., Friedman, G., Castro, R., Alegría, L., Teboul, J.-L., et al. (2019) · JAMA · doi:10.1001/jama.2019.0071 · Cited by 946
Self-citationCecconi, M., Hernandez, G., Dunser, M., Antonelli, M., Baker, T., Bakker, J., Duranteau, J., Einav, S., Groeneveld, A. B. J., Harris, T., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-018-5415-2 · Cited by 128
Self-citationKattan, E., Hernández, G., Ospina-Tascón, G., Valenzuela, E. D., Bakker, J., & Castro, R. (2020) · Annals of Intensive Care · doi:10.1186/s13613-020-00732-1 · Cited by 100
Self-citation
Metadata
- Authors
- The ANDROMEDA-SHOCK Study Investigators, Hernández, G., Cavalcanti, A. B., Ospina-Tascón, G., Zampieri, F. G., Dubin, A., Hurtado, F. J., Friedman, G., Castro, R., Alegría, L., Cecconi, M., Teboul, J.-L., & Bakker, J.
- Venue
- Annals of Intensive Care
- Publisher
- Elsevier BV
- Published
- 2018-04-23
- Volume
- 8
- Issue
- 1
- Pages
- 52-52
- ISSN
- 2110-5820 (ISSN-L)
- OpenAlex
- W2807221187
- Cited by
- 85
- References
- 6
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK—a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13613-018-0398-2
- The paper
- The ANDROMEDA-SHOCK Study Investigators, Hernández, G., Cavalcanti, A. B., Ospina-Tascón, G., Zampieri, F. G., Dubin, A., Hurtado, F. J., Friedman, G., Castro, R., Alegría, L., Cecconi, M., Teboul, J.-L., & Bakker, J. (2018). Early goal-directed therapy using a physiological holistic view: the ANDROMEDA-SHOCK—a randomized controlled trial. Annals of Intensive Care. https://doi.org/10.1186/s13613-018-0398-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.